Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ajanta PharmaBOM:532331 -0.69%95 Net Margin % is 20.56% as of Jun. 2026, which is 4% above its 10-year median of 19.84. GuruFocus rates BOM:532331 with a GF Score™ of 95/100 and a GF Value™ of ₹3,348.50 (Fairly Valued). The stock has 6 warning signs investors should review. Among 960 Drug Manufacturers companies, Ajanta Pharma ranks better than 86.98% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Ajanta Pharma's Net Income for the
three
months ended in Jun. 2026 was ₹3,342 Mil. Ajanta Pharma's Revenue for the
three
months ended in Jun. 2026 was ₹16,260 Mil. Therefore, Ajanta Pharma's net margin for the quarter that ended in Jun. 2026 was 20.56%.
The historical rank and industry rank for Ajanta Pharma's Net Margin % or its related term are showing as below:
BOM:532331'
s Net Margin % Range Over the Past 10 Years
Min: 15.86 Med: 19.84 Max: 26.45
Current: 19.65
BOM:532331's Net Margin % is ranked better than 86.98% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.205
vs BOM:532331: 19.65
Ajanta Pharma (BOM:532331) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Ajanta Pharma Net Margin % Related Terms
Ajanta Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Ajanta Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ajanta Pharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Ajanta Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ajanta Pharma (BOM:532331) has a Net Margin % of 20.56% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Ajanta Pharma and its competitors. This is near median its historical median of 19.84. Over the past decade, Ajanta Pharma's Net Margin % has ranged from 15.86 to 26.45. According to the industry distribution chart, Ajanta Pharma ranks #125 out of 960 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is Ajanta Pharma's Net Margin % too high?
Ajanta Pharma's current Net Margin % of 20.56% is near median its 10-year median of 19.84. Over the past 10 years, this metric has ranged from a low of 15.86 to a high of 26.45. The Drug Manufacturers industry median Net Margin % is 5.21. Ajanta Pharma's value of 20.56% is 295% above this industry median. Based on the distribution chart, Ajanta Pharma ranks #125 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ajanta Pharma has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ajanta Pharma's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ajanta Pharma ranks #125 out of 960 companies for Net Margin %. This places Ajanta Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.21. Ajanta Pharma's value of 20.56% is 295% above this benchmark. Historically, Ajanta Pharma's own Net Margin % has ranged from 15.86 to 26.45 over the past decade. While the company's 10-year median is 19.84 vs. the industry median of 5.21, Ajanta Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.21, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ajanta Pharma's current Net Margin % of 20.56% is 295% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ajanta Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ajanta Pharma's current Net Margin % is 20.56%, which is near median its own 10-year median of 19.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajanta Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ajanta Pharma (BOM:532331) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,348.50, compared to a current price of ₹3,480.95 — trading 4% above its estimated fair value. The current Net Margin % is 20.56%, which is near median its 10-year median of 19.84 and 295% above the Drug Manufacturers industry median of 5.21. Ajanta Pharma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ajanta Pharma (BOM:532331), the current Net Margin % is 20.56% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ajanta Pharma (BOM:532331) Overvalued in 2026?
Based on GuruFocus' analysis, Ajanta Pharma stock appears to be overvalued.
The current stock price of ₹3,480.95 is trading 4% above its estimated GF Value™ of ₹3,348.50.
GuruFocus considers Ajanta Pharma to be Fairly Valued.
Key valuation signals for BOM:532331:
Net Margin %: 20.56% (near median its 10-year median of 19.84)
GF Value™: ₹3,348.50 vs. price of ₹3,480.95 (4% above fair value)
Industry Position: 295% above the Drug Manufacturers median (#125 of 960)
No single metric tells the full story. See the BOM:532331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ajanta Pharma Ltd is mainly involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages. The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. The company has presence in India, Emerging Market, Africa Institution, and USA. The company generates majority of revenue from Emerging market.
95GF Score
Get the complete analysis for BOM:532331
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532331 has been successfully added to your 
